Pfizer to end license deal with Syros for blood disorder therapies

July 21 (Reuters) – Syros Pharmaceuticals (SYRS.O) said on Friday Pfizer (PFE.N) will terminate a license deal between the companies related to the development of novel therapies for two blood disorders.

Shares of Syros were down 5.7% in trading after the bell.

The termination will end the company’s more than three-year long collaboration with sickle cell disease drugmaker Global Blood Therapeutics (GBT) that Pfizer bought in a $5.4 billion deal last August.

The partnership for sickle cell disease and beta thalassemia – diseases that affect the production and nature of hemoglobin in the blood is set to end on Oct. 16, the company said.

Syros “intends to seek to identify a new out-licensing partner for its sickle cell disease program,” it added.

Our Standards: The Thomson Reuters Trust Principles.